Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Prestige Consumer Healthcare Q2 2026 Results: Net Income $25.3M, Down 40.1% YoY

Prestige Consumer Healthcare reported total revenues of $336.3 million for the quarter ended September 30, 2026, up from $274.1 million in the prior year, though net income decreased to $25.3 million due to higher interest expenses and acquisition-related costs. The company significantly expanded its balance sheet through a $1.19 billion acquisition, funded by new term loans and senior notes.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue336.3274.1
Gross profit172.5151.6
Net income25.342.2
EPS (diluted, $ a share)$0.53$0.86

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-40.1%
Revenue, year on year+22.7%
Gross margin51.3%
Operating margin24.0%
Source

10-Q filed with the SEC, NYSE: PBH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Prestige Consumer Healthcare Inc.: key numbers

Share price
$48.00Close, Nov 16
Market cap
$2.28B
Shares outstanding
47.4MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Prestige Consumer Healthcare Inc.

All →
6:05 AM ET 8-K
Financial Results

Prestige Consumer Healthcare Financial Results

Prestige Consumer Healthcare reported Q2 fiscal 2027 revenue of $336.3 million, a 22.7% increase driven by the acquisitions of Breathe Right and LaCorium. Adjusted diluted EPS rose to $1.13 from $1.07 in the prior year, supported by strong consumption across eCommerce channels. The company adjusted its full-year revenue guidance to a range of $1.28 billion to $1.29 billion.

Term
Q2 2027

“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward.”

Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.